BioCentury
ARTICLE | Financial News

Gene therapy company Audentes raises $151M

October 12, 2018 6:18 PM UTC

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million on Oct. 10 through the sale of 5.2 million shares at $29 in a follow-on underwritten by BofA Merrill Lynch, J.P. Morgan, Cowen and Wedbush PacGrow. The price is a 21% discount to Audentes' close of $36.70 on Oct. 9, when it proposed to raise $150 million.

The company slid 19% on Oct. 10 before pricing the offering after market hours. It lost another $2.70 to $27.13 on Oct. 11...

BCIQ Company Profiles

Audentes Therapeutics Inc.

BCIQ Target Profiles

Myotubularin 1 (MTM1)